Form 6-K Steakholder Foods Ltd. For: May 20

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE MONTH OF MAY 2026

 

COMMISSION FILE NUMBER 001-40173

 

Steakholder Foods Ltd.

(Translation of registrant’s name into English)

 

Steakholder Foods Ltd.

22 Einstein St., Ness Ziona, Israel 7403686

+972 8-974-0000

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

 

Form 20-F ☒     Form 40-F ☐

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

On May 20, 2026, Steakholder Foods Ltd. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing the upcoming launch of Perfecta premium plant-based meat in the U.S. market.

 

This Form 6-K is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933, as amended.

 

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.1		Press release, dated May 20, 2026

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Steakholder Foods Ltd.
	By:	/s/ Arik Kaufman
		Name:	Arik Kaufman
		Title:	Chief Executive Officer
Date: May 20, 2026

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE, DATED MAY 20, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Steakholder Foods ships plant-based meat line to the U.S.
• Hadrius Raises $27 Million to Build Agentic Compliance Infrastructure
• HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction